Skip to content

    Alembic Pharmaceuticals Limited

    APLLTDGood
    Healthcare·4 Nov 2025
    Management Summary

    Alembic Pharma delivered a strong Q2 FY26, characterized by robust double-digit growth in international markets and significant operating leverage. While the India business faced temporary GST-related disruptions, the US and ROW segments outperformed. Management is pivoting towards a higher-margin profile by targeting 20% EBITDA margins in the next two years and entering the US branded specialty space.

    Highlights

    8
    • Revenue grew 16% YoY to ₹1,910 crores, driven by volume growth and new launches.

    • EBITDA (before R&D) stood at ₹503 crores with a margin of 26%, up from 23% YoY.

    • PAT (before exceptional items) increased 30% YoY to ₹185 crores.

    • US business grew 21% YoY, supported by the launch of Entresto and higher volumes.

    • Rest of World (ROW) markets delivered exceptional 31% growth.

    • R&D spend increased 41% YoY to ₹187 crores (~10% of revenue) due to complex injectable and peptide development.

    • Company announced entry into US branded market with the acquisition of Utility Therapeutics and the product 'Pivya'.

    • Net debt increased to ₹1,280 crores from ₹967 crores in June '25, primarily to fund working capital and acquisitions.

    What Changed2

    vs Q3 FY26

    Guidance items7 → 5 (-2)Q&A highlights6 → 3 (-3)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹1,910 Cr+16%YoY
    2. 02EBITDA Margin (before R&D)26%
    3. 03PAT (before exceptional)₹185 Cr+30%YoY
    4. 04R&D Spend₹187 Cr+41%YoY
    5. 05Gross Margin73%0%YoY

    Segment breakdown

    India Branded Business
    ₹639 Cr Revenue5% Growth
    US Business
    21% Growth3 count New Launches
    Rest of World (ROW)
    31% Growth85% Regulated Market Mix
    API Business
    15% Growth
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    20%
    Medium
    Other
    R&D Spend
    ₹600-650 crores
    High
    Revenue
    ROW Generics Growth
    15% to 20%
    Medium
    Revenue
    API Growth
    10%
    Medium
    Margin
    Gross Margin Range
    70% to 75%
    High

    Risks & concerns

    5
    RiskSeverity

    US Generic Pricing Erosion

    Management noted pricing pressure in US Generics and specifically mentioned erosion in the large Entresto launch.Management acknowledged

    medium

    Near-term Profitability Hit from US Branded Entry

    Onboarding a field force for Pivya will impact margins for a few quarters before revenue ramps up.Management acknowledged

    low

    GST 2.0 Implementation Disruptions

    Billing was paused for a few days in India to facilitate migration, marginally impacting Q2 growth.Both acknowledged

    low

    Areas of Evasion(2)

    • Specific budgeted investment amounts for the US specialty field force.
    • Plant-level utilization percentages.

    Q&A highlights

    3

    “We've done batches of tirzepatide, the Mounjaro right now, which has caused a little bit of a bump up in the R&D costs for this quarter.”

    Explains the 41% YoY jump in R&D and confirms Alembic's active development of high-value GLP-1 peptides.

    asked by Damayanti Kerai, HSBC Bank

    2 min read5 chapters

    Detailed Narrative

    01

    International Markets Drive Outperformance

    Alembic's international business was the primary growth engine this quarter, with US revenue growing 21% and ROW markets surging 31%. The US growth was underpinned by the successful launch of Entresto and three other products, despite ongoing pricing erosion. In ROW, 85% of the business now comes from regulated markets like Europe, Canada, and Australia, where the company maintains a 20% CAGR over the long term.

    02

    Strategic Pivot to US Branded Specialty

    The acquisition of Utility Therapeutics marks Alembic's entry into the US branded market with Pivya, a product for urinary tract infections. The deal involves a $4 million upfront payment and $12 million in total milestones. While the launch in late Q4 FY26 will require a dedicated field force and cause a near-term profitability hit, management views this as a critical de-risking strategy from the volatile generic business.

    03

    R&D Focus on Complex Generics and Peptides

    R&D spend reached 10% of revenue this quarter, driven by development in complex injectables and peptides. Management confirmed they are working on Tirzepatide (Mounjaro) and have already produced batches, contributing to the cost spike. Despite the quarterly increase, the company maintained its full-year R&D guidance of ₹600-650 crores, expecting the ratio to normalize to 8% by year-end.

    04

    Margin Expansion Path to 20%

    Management has set a clear target to reach 20% EBITDA margins within the next two years. This expansion is expected to come from operating leverage as utilization increases at the new injectable and oncology facilities, which are currently running at lower-than-anticipated levels. Improved productivity in the India field force and a shift toward higher-value complex products are also cited as key margin drivers.

    05

    India Business Navigates GST Transition

    The India Branded Business grew a modest 5% YoY to ₹639 crores, impacted by a temporary billing pause during the migration to GST 2.0. While segments like Gynecology and Animal Health outperformed, the core acute business faced a high base effect from the previous year. Management expects growth to catch up📎 with the Indian Pharmaceutical Market (IPM) as productivity improvements in the field force take hold in FY27.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.